Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 185 participants.

Also called NCT01652001

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 185 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01652001
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01652001. Randomized; double masking; primary purpose treatment. Start 2011-01 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2016-04-05.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Drug-induced Xerostomia. Evaluation of Malic Acid 1%, Salivary Mucins and Buffering Capacity
Condition
Xerostomia
Condition
Depression
Condition
Hypertension
Intervention (Drug)
Malic Acid
Intervention (Other)
Placebo
Lead sponsor
Universidad de Granada (class: other)
Collaborator
Instituto de Salud Carlos III (class: other government)

Record details

Record id
cardio:ct-nct01652001
Content hash
37a1bf8ca5236b2da0aa1adbc5d9261798d69ac7c85356dae71eec4b4889a09a